Nurix、第2四半期の純損失拡大、収入減少もロシュとの7億ドル契約を強調

Roche enters collaboration to co-develop and co-commercialize Nurix's BTK degrader bexobrutide, gaining access to a promising drug.

Wider net loss and lower revenue are negative, but the $700 million upfront from Roche deal and potential $2.3 billion total outweigh, with strong cash position.